bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Trends in Radiation Therapy among Cancer Survivors in the United States, 2000–2030
Authors: Bryant Alex K. , Banegas Matthew P. , Martinez Maria Elena , Mell Loren K. , Murphy James D.
Published: April 2023

Abstract
Background: Although the number of cancer survivors has increased substantially over the past several decades, the composition of survivors treated with radiotherapy is not well defined. Radiotherapy carries unique long-term toxicity risks for cancer survivors. This study describes the current estimates and future projections of the epidemiology of 5-year cancer survivors who receive radiation therapy.

Methods: We used cancer incidence and survival data from the Surveillance, Epidemiology, and End-Results (SEER) database linked to U.S. Census data to estimate the number of 5-year cancer survivors treated with radiation between 2000 and 2030. Future projections assumed continuing incidence and survival trends based on historical rates.

Results: In 2016, there were an estimated 3.05 million cancer survivors treated with radiation, accounting for 29% of all cancer survivors. The number of radiation-treated cancer survivors is projected to reach 3.38 million by 2020 and 4.17 million by 2030. In 2016, breast (40%) and prostate cancer (23%) composed the majority of radiation-treated survivors, followed by head and neck cancer (5.8%), lymphoma (5.6%), uterine (3.9%), and rectal cancer (3.8%). The percentage of 70 years or older radiation-treated survivors steadily increased between 2000 and 2030.

Conclusions: The next several years are projected to see a large increase in the number of cancer survivors treated with radiation.

Impact: This group of cancer survivors has unique needs given the long-term risks of radiation, and increased research and awareness are required to optimize health of this growing population. Cancer Epidemiol Biomarkers Prev; 26(6); 963–70. ©2017 AACR.
Data from Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Authors: Mariotto Angela B. , Etzioni Ruth , Hurlbert Marc , Penberthy Lynne , Mayer Musa
Published: April 2023

Abstract
Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC.

Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness–death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease.

Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I–III breast cancer who later progressed to MBC.

Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18% to 36%, for women diagnosed with de novo MBC at age 15–49 between 1992–1994 and 2005–2012, respectively.

Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. population.

Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population. Cancer Epidemiol Biomarkers Prev; 26(6); 809–15. ©2017 AACR.
Data from No Association between the Mitochondrial Genome and Prostate Cancer Risk: The Multiethnic Cohort
Authors: Giorgi Elena E. , Li Yuqing , Caberto Christian P. , Beckman Kenneth B. , Lum-Jones Annette , Haiman Christopher A. , Le Marchand Loïc , Stram Daniel O. , Saxena Richa , Cheng Iona
Published: April 2023

Abstract
Background: Mitochondria are involved in many processes that are central to the life and death of a cell. Oxidative phosphorylation (OXPHOS), in particular, is known to be altered in carcinogenesis, leading to an increase in the production of reactive oxidative species and glycolysis, one of the hallmarks of cancer cells. Because of this, genetic variation in the mitochondrial genome, which encodes for part of the OXPHOS pathway, has been suggested to play a role in many cancers, including prostate cancer.

Methods: We comprehensively examined the role of the mitochondrial genome and prostate cancer risk in 4,086 prostate cancer cases and 3,698 controls from the Multiethnic Cohort (MEC), testing 350 mitochondrial SNPs (mtSNPs) in five racial/ethnic populations—Africans, Asian Americans, Europeans, Latinos, and Native Hawaiians. Logistic regression was conducted to examine single mitochondrial SNP and haplogroup associations. The sequence kernel association test was conducted for gene and pathway analysis.

Results: Eleven mtSNPs and haplogroup N were nominally associated with overall prostate cancer risk at P < 0.05. The mitochondrial DNA-encoded OXPHOS pathway, complexes, and genes were not associated with prostate cancer risk. No significant associations were identified after multiple testing corrections (all FDR q > 0.20).

Conclusions: The mitochondrial genome was not associated with prostate cancer risk in our study of 7,784 subjects from the MEC.

Impact: Our comprehensive study does not support the role of the mitochondrial genome in the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev; 25(6); 1001–3. ©2016 AACR.
Data from Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression
Authors: Park Jong Y. , Amankwah Ernest K. , Anic Gabriella M. , Lin Hui-Yi , Walls Brooke , Park Hyun , Krebs Kevin , Madden Melissa , Maddox Kristen , Marzban Suroosh , Fang Shenying , Chen Wei , Lee Jeffrey E. , Wei Qingyi , Amos Christopher I. , Messina Jane L. , Sondak Vernon K. , Sellers Thomas A. , Egan Kathleen M.
Published: April 2023

Abstract
Background: Angiogenesis and lymphangiogenesis are important in the progression of melanoma. We investigated associations between genetic variants in these pathways with sentinel lymph node (SLN) metastasis and mortality in 2 independent series of patients with melanoma.

Methods: Participants at Moffitt Cancer Center were 552 patients, all Caucasian, with primary cutaneous melanoma referred for SLN biopsy. A total of 177 patients had SLN metastasis, among whom 60 died from melanoma. Associations between 238 single-nucleotide polymorphisms (SNP) in 26 genes and SLN metastasis were estimated as ORs and 95% confidence intervals (CI) using logistic regression. Competing risk regression was used to estimate HRs and 95% CI for each SNP and melanoma-specific mortality. We attempted to replicate significant findings using data from a genome-wide association study comprising 1,115 patients with melanoma who were referred for SLN biopsy from MD Anderson Cancer Center (MDACC), among whom 189 patients had SLN metastasis and 92 patients died from melanoma.

Results: In the Moffitt dataset, we observed significant associations in 18 SNPs with SLN metastasis and 17 SNPs with mortality. Multiple SNPs in COL18A1, EGF receptor (EGFR), FLT1, interleukin (IL)-10, platelet-derived growth factor D (PDGFD), PIK3CA, and toll-like receptor (TLR)-3 were associated with the risk of SLN metastasis and/or patient mortality. The MDACC data set replicated an association between mortality and rs2220377 in PDGFD. Furthermore, in a meta-analysis, 3 additional SNPs were significantly associated with SLN metastasis (EGFR rs723526 and TLR3 rs3775292) and melanoma-specific death (TLR3 rs7668666).

Conclusions: These findings suggest that genetic variation in angiogenesis and lymphangiogenesis contributes to regional nodal metastasis and progression of melanoma.

Impact: Additional research attempting to replicate these results is warranted. Cancer Epidemiol Biomarkers Prev; 22(5); 827–34. ©2013 AACR.
Data from Genetic Polymorphisms in Pre-microRNA Genes as Prognostic Markers of Colorectal Cancer
Authors: Xing Jinliang , Wan Shaogui , Zhou Feng , Qu Falin , Li Bingshan , Myers Ronald E. , Fu Xiaoying , Palazzo Juan P. , He Xianli , Chen Zhinan , Yang Hushan
Published: April 2023

Abstract
Background: Cumulative data have shown that microRNAs (miRNA) are involved in the etiology and prognosis of colorectal cancer (CRC). Genetic polymorphisms in pre-miRNA genes may influence the biogenesis and functions of their host miRNAs. However, whether these polymorphisms are associated with CRC prognosis remains unknown.

Methods: We analyzed the effects of seven single-nucleotide polymorphisms (SNP) in pre-miRNA genes on the prognosis of a Chinese population with 408 CRC patients with surgically-resected adenocarcinoma.

Results: Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared with the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR = 2.12, 95% CI = 1.34–3.34, P = 0.001) and the recurrence-free survival (HR = 1.59, 95% CI = 1.08–2.36, P = 0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR = 0.61, 95% CI = 0.41–0.92, P = 0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI = 1.50–5.37, P = 0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P < 0.001) but not in those without chemotherapy (P = 0.999).

Conclusions: Our data suggest that genetic polymorphisms in pre-miRNA genes may impact CRC prognosis especially in patients receiving chemotherapy, a finding that warrants further independent validation.

Impact: This is one of the first studies showing a prognostic role of pre-miRNA gene SNPs in CRC. Cancer Epidemiol Biomarkers Prev; 21(1); 217–27. ©2011 AACR.
Data from Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era
Authors: Malagón Talía , Drolet Mélanie , Boily Marie-Claude , Laprise Jean-François , Brisson Marc
Published: April 2023

Abstract
Background: Inequalities in cervical cancer may be increased following mass vaccination against the human papillomavirus (HPV) if girls with low vaccine uptake also have low future participation in cervical cancer screening. We evaluated how vaccine uptake distribution affects inequalities in squamous cell carcinoma (SCC) incidence between groups with different screening participation.

Methods: We used an individual-based transmission dynamic model of HPV infection and disease (HPV-ADVISE). Females were stratified by routine screening frequency. We modeled the impact of vaccination on SCC incidence rate differences (absolute inequality) and incidence rate ratios (relative inequality) between women who have routine screening intervals of <5 years (frequently screened), ≥5 years (underscreened), and who are never screened. We compared simulations with uniform vaccine uptake with scenarios with unequal vaccine uptake, in which never and underscreened women have lower vaccine uptake than frequently screened women.

Results: Absolute SCC inequalities between groups with different screening rates were predicted to decrease after vaccination, even when women with the lowest screening participation had the lowest vaccine uptake. Herd effects helped reduce absolute inequalities when vaccine uptake was unequal. Conversely, relative SCC inequalities remained unchanged or increased after vaccination. Results were robust to different overall vaccination coverages and sexual mixing scenarios.

Conclusion: Though mass HPV vaccination is predicted to substantially decrease SCC incidence rates, never screened women will still have the highest disease burden after vaccination.

Impact: To reduce both absolute and relative SCC inequalities, public health initiatives will need to address inequalities in both vaccine uptake and in cervical cancer screening participation. Cancer Epidemiol Biomarkers Prev; 24(1); 276–85. ©2014 AACR.
Supplementary Movie S5 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Authors: Jackson Lindsey N. , Chen L. Andy , Larson Shawn D. , Silva Scott R. , Rychahou Piotr G. , Boor Paul J. , Li Jing , DeFreitas Gilberto , Stafford W. Lane , Townsend Courtney M. , Evers B. Mark
Published: April 2023

Supplementary Movie S5 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Supplementary Table S1 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Authors: Ribas Antoni , Comin-Anduix Begoña , Chmielowski Bartosz , Jalil Jason , de la Rocha Pilar , McCannel Tara A. , Ochoa Maria Teresa , Seja Elizabeth , Villanueva Arturo , Oseguera Denise K. , Straatsma Bradley R. , Cochran Alistair J. , Glaspy John A. , Hui Liu , Marincola Francesco M. , Wang Ena , Economou James S. , Gomez-Navarro Jesus
Published: April 2023

Supplementary Table S1 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Supplementary Figure Legend from Species D Adenoviruses as Oncolytics against B-cell Cancers
Authors: Chen Christopher Y. , Senac Julien S. , Weaver Eric A. , May Shannon M. , Jelinek Diane F. , Greipp Philip , Witzig Thomas , Barry Michael A.
Published: April 2023

PDF file - 56KB
Supplementary Figure 2 from Species D Adenoviruses as Oncolytics against B-cell Cancers
Authors: Chen Christopher Y. , Senac Julien S. , Weaver Eric A. , May Shannon M. , Jelinek Diane F. , Greipp Philip , Witzig Thomas , Barry Michael A.
Published: April 2023

PDF file - 233KB
Supplementary Figure 3 from Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
Authors: Serganova Inna , Rizwan Asif , Ni Xiaohui , Thakur Sunitha B. , Vider Jelena , Russell James , Blasberg Ronald , Koutcher Jason A.
Published: April 2023

PDF file - 790K
Supplementary Figure 2 from Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
Authors: Urick Mary Ellen , Chung Eun Joo , Shield William P. , Gerber Naamit , White Ayla , Sowers Anastasia , Thetford Angela , Camphausen Kevin , Mitchell James , Citrin Deborah E.
Published: April 2023

PDF file - 69K
Supplementary Figure Legends 1-2 from Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases
Authors: de Miranda Noel F.C.C. , Goudkade Danny , Jordanova Ekaterina S. , Tops Carli M.J. , Hes Frederik J. , Vasen Hans F.A. , van Wezel Tom , Morreau Hans
Published: April 2023

PDF file - 34K
Supplementary Figure 1 from Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases
Authors: de Miranda Noel F.C.C. , Goudkade Danny , Jordanova Ekaterina S. , Tops Carli M.J. , Hes Frederik J. , Vasen Hans F.A. , van Wezel Tom , Morreau Hans
Published: April 2023

PDF file - 289K
Supplementary Figure 1 from Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Authors: Yoon Harry H. , Shi Qian , Sukov William R. , Wiktor Anne E. , Khan Maliha , Sattler Christopher A. , Grothey Axel , Wu Tsung-Teh , Diasio Robert B. , Jenkins Robert B. , Sinicrope Frank A.
Published: April 2023

PDF file - 790K
Supplementary Figure 1 from A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Authors: Mohebtash Mahsa , Tsang Kwong-Yok , Madan Ravi A. , Huen Ngar-Yee , Poole Diane J. , Jochems Caroline , Jones Jacquin , Ferrara Theresa , Heery Christopher R. , Arlen Philip M. , Steinberg Seth M. , Pazdur Mary , Rauckhorst Myrna , Jones Elizabeth C. , Dahut William L. , Schlom Jeffrey , Gulley James L.
Published: April 2023

PDF file - 101K
Supplementary Methods and Results from Specific PET Imaging of xC− Transporter Activity Using a 18F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism
Authors: Koglin Norman , Mueller Andre , Berndt Mathias , Schmitt-Willich Heribert , Toschi Luisella , Stephens Andrew W. , Gekeler Volker , Friebe Matthias , Dinkelborg Ludger M.
Published: April 2023

PDF file- 354K, Detailed information on chemistry, radiochemistry and additional biological characterization
Acknowledgements List from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Authors: de Fraipont Florence , Levallet Guénaëlle , Creveuil Christian , Bergot Emmanuel , Beau-Faller Michèle , Mounawar Mounia , Richard Nicolas , Antoine Martine , Rouquette Isabelle , Favrot Marie-Christine , Debieuvre Didier , Braun Denis , Westeel Virginie , Quoix Elisabeth , Brambilla Elisabeth , Hainaut Pierre , Moro-Sibilot Denis , Morin Franck , Milleron Bernard , Zalcman Gérard
Published: April 2023

PDF file - 21K, Acknowledegements to IFCT staff (administrative and CRAs), to expert pathological panel, and list of investigators of the phase 3 clinical trial IFCT 0002
Supplementary Materials and Methods from Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
Authors: Kilday John-Paul , Mitra Biswaroop , Domerg Caroline , Ward Jennifer , Andreiuolo Felipe , Osteso-Ibanez Teresa , Mauguen Audrey , Varlet Pascale , Le Deley Marie-Cecile , Lowe James , Ellison David W. , Gilbertson Richard J. , Coyle Beth , Grill Jacques , Grundy Richard G.
Published: April 2023

PDF file - 92K, Provides an overview of the three therapeutic trial cohorts analysed in this study.Also contains extra methodology for the SNP array analysis, the iFISH analysis and a detailed account of the statistics used in this work.
Supplementary Figure 1 from Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
Authors: Kilday John-Paul , Mitra Biswaroop , Domerg Caroline , Ward Jennifer , Andreiuolo Felipe , Osteso-Ibanez Teresa , Mauguen Audrey , Varlet Pascale , Le Deley Marie-Cecile , Lowe James , Ellison David W. , Gilbertson Richard J. , Coyle Beth , Grill Jacques , Grundy Richard G.
Published: April 2023

PDF file - 74K, Spotfire Spotfire Decision Site� copy number heatmap demonstrating Affymetrix� 500K SNP array results across the genome for 42 primary and six intracranial first recurrent pediatric ependymomas.
Supplementary Figure 2 from A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma
Authors: Shan Weiwei , Akinfenwa Patricia Y. , Savannah Kari B. , Kolomeyevskaya Nonna , Laucirica Rudolfo , Thomas Dafydd G. , Odunsi Kunle , Creighton Chad J. , Lev Dina C. , Anderson Matthew L.
Published: April 2023

PDF file, 1041KB, Impact of combining MK-5108 with chemotherapeutic reagents on cell proliferation in ULMS cell lines.
Supplementary Figure 1 from A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma
Authors: Shan Weiwei , Akinfenwa Patricia Y. , Savannah Kari B. , Kolomeyevskaya Nonna , Laucirica Rudolfo , Thomas Dafydd G. , Odunsi Kunle , Creighton Chad J. , Lev Dina C. , Anderson Matthew L.
Published: April 2023

PDF file, 2676KB, Impact of MK-5108 on phospho-MPM2 staining in ULMS cell lines.
Supplementary Figure 3 from Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor
Authors: Zeng Zhaolei , Lin Huanxin , Zhao Xiaohui , Liu Guanglin , Wang Xi , Xu Ruihua , Chen Kun , Li Jun , Song Libing
Published: April 2023

PDF file - 65K, Kaplan-Meier overall survival curves and log-rank test of overall survival
Supplementary Table 2 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
Authors: Suzuki Kei , Kachala Stefan S. , Kadota Kyuichi , Shen Ronglai , Mo Qianxing , Beer David G. , Rusch Valerie W. , Travis William D. , Adusumilli Prasad S.
Published: April 2023

Supplementary Table 2 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
Supplementary Figures S1-S2 from Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation Using PET
Authors: Rygh Cecilie B. , Qin Shengping , Seo Jai W. , Mahakian Lisa M. , Zhang Hua , Adamson Roger , Chen Jane Q. , Borowsky Alexander D. , Cardiff Robert D. , Reed Rolf K. , Curry Fitz-Roy E. , Ferrara Katherine W.
Published: April 2023

Supplementary Figures S1-S2.
Supplementary Figure 1 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
Authors: Suzuki Kei , Kachala Stefan S. , Kadota Kyuichi , Shen Ronglai , Mo Qianxing , Beer David G. , Rusch Valerie W. , Travis William D. , Adusumilli Prasad S.
Published: April 2023

Supplementary Figure 1 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
Supplementary Figure 1 from A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
Authors: Lewis Carol M. , Glisson Bonnie S. , Feng Lei , Wan Fiona , Tang Ximing , Wistuba Ignacio I. , El-Naggar Adel K. , Rosenthal David I. , Chambers Mark S. , Lustig Robert A. , Weber Randal S.
Published: April 2023

PDF file - 251K
Supplementary Table 2 from Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Authors: Tarhini Ahmad A. , Frankel Paul , Margolin Kim A. , Christensen Scott , Ruel Christopher , Shipe-Spotloe Janice , Gandara David R. , Chen Alice , Kirkwood John M.
Published: April 2023

PDF file - 15K
Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Authors: Turley Ryan S. , Fontanella Andrew N. , Padussis James C. , Toshimitsu Hiroaki , Tokuhisa Yoshihiro , Cho Eugenia H. , Hanna Gabi , Beasley Georgia M. , Augustine Christina K. , Dewhirst Mark W. , Tyler Douglas S.
Published: April 2023

PDF file, 126KB, Human melanoma cells secrete VEGF which is effectively neutralized by bevacizumab.
Supplementary Table 2 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
Authors: Park Steven I. , Shenoi Jaideep , Frayo Shani M. , Hamlin Donald K. , Lin Yukang , Wilbur D. Scott , Stayton Patrick S. , Orgun Nural , Hylarides Mark , Buchegger Franz , Kenoyer Aimee L. , Axtman Amanda , Gopal Ajay K. , Green Damian J. , Pagel John M. , Press Oliver W.
Published: April 2023

PDF file - 63K
Supplementary Figures S1-S5 from Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Authors: Nagaraj Nagathihalli S. , Washington M. Kay , Merchant Nipun B.
Published: April 2023

Supplementary Figures S1-S5.
Supplementary Table 4 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
Authors: Stutterheim Janine , Ichou Fatima Ait , den Ouden Emmy , Versteeg Rogier , Caron Huib N. , Tytgat Godelieve A.M. , van der Schoot C. Ellen
Published: April 2023

PDF file - 51K
Supplementary Figure 1b from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
Authors: Stutterheim Janine , Ichou Fatima Ait , den Ouden Emmy , Versteeg Rogier , Caron Huib N. , Tytgat Godelieve A.M. , van der Schoot C. Ellen
Published: April 2023

PDF file - 43K
Supplementary Table 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
Authors: de Weger Vincent A. , Turksma Annelies W. , Voorham Quirinus J.M. , Euler Zelda , Bril Herman , van den Eertwegh Alfons J. , Bloemena Elisabeth , Pinedo Herbert M. , Vermorken Jan B. , van Tinteren Harm , Meijer Gerrit A. , Hooijberg Erik
Published: April 2023

PDF file - 66K
Supplementary Figure 4 from Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors
Authors: Klopp Ann H. , Zhang Yan , Solley Travis , Amaya-Manzanares Felipe , Marini Frank , Andreeff Michael , Debeb Bisrat , Woodward Wendy , Schmandt Rosemarie , Broaddus Russell , Lu Karen , Kolonin Mikhail G.
Published: April 2023

PDF file - 139K, Endometrial Hec1a cancer cell proliferation in co-culture with OSC, MSC, ASC and WI38 fibroblasts.
Supplementary Figure 2 from Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors
Authors: Klopp Ann H. , Zhang Yan , Solley Travis , Amaya-Manzanares Felipe , Marini Frank , Andreeff Michael , Debeb Bisrat , Woodward Wendy , Schmandt Rosemarie , Broaddus Russell , Lu Karen , Kolonin Mikhail G.
Published: April 2023

PDF file - 678K, O-ASC do not co-localize with CD31 positive endothelial cells.
Supplementary Figure Legends 1-2 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Authors: Ogino Shuji , Shima Kaori , Meyerhardt Jeffrey A. , McCleary Nadine J. , Ng Kimmie , Hollis Donna , Saltz Leonard B. , Mayer Robert J. , Schaefer Paul , Whittom Renaud , Hantel Alexander , Benson Al B. , Spiegelman Donna , Goldberg Richard M. , Bertagnolli Monica M. , Fuchs Charles S.
Published: April 2023

PDF file - 57K
Supplementary Figure 1 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Authors: Ogino Shuji , Shima Kaori , Meyerhardt Jeffrey A. , McCleary Nadine J. , Ng Kimmie , Hollis Donna , Saltz Leonard B. , Mayer Robert J. , Schaefer Paul , Whittom Renaud , Hantel Alexander , Benson Al B. , Spiegelman Donna , Goldberg Richard M. , Bertagnolli Monica M. , Fuchs Charles S.
Published: April 2023

PDF file - 42K, Distribution of stage III colon cancer according to MSI, KRAS and BRAF status.
Supplementary Figure 3 from Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
Authors: Ciarimboli Giuliano , Lancaster Cynthia S. , Schlatter Eberhard , Franke Ryan M. , Sprowl Jason A. , Pavenstädt Hermann , Massmann Vivian , Guckel Denise , Mathijssen Ron H. J. , Yang Wenjian , Pui Ching-Hon , Relling Mary V. , Herrmann Edwin , Sparreboom Alex
Published: April 2023

PDF file - 40K
Supplementary Figure Legend 1 from Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Authors: Steg Adam D. , Bevis Kerri S. , Katre Ashwini A. , Ziebarth Angela , Dobbin Zachary C. , Alvarez Ronald D. , Zhang Kui , Conner Michael , Landen Charles N.
Published: April 2023

PDF file - 45K
Supplementary Table 6C from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 52K
Supplementary Table 3 from Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Authors: Riester Markus , Taylor Jennifer M. , Feifer Andrew , Koppie Theresa , Rosenberg Jonathan E. , Downey Robert J. , Bochner Bernard H. , Michor Franziska
Published: April 2023

XLS file - 1.4MB
Supplementary Table 5A from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 1949K
Supplementary Table 1 from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 50K
Supplementary Figure 2 from Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Authors: Hudecek Michael , Lupo-Stanghellini Maria-Teresa , Kosasih Paula L. , Sommermeyer Daniel , Jensen Michael C. , Rader Christoph , Riddell Stanley R.
Published: April 2023

PDF File - 83K, Supplementary Figure 2: Analysis of cytokine production and proliferation of CD4+ T-cells lines modified with a ROR1-CAR derived from mAb R12 with higher affinity than 2A2.
Supplementary Figures 1 - 9 from Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
Authors: Bogusz Agata M. , Baxter Richard H.G. , Currie Treeve , Sinha Papiya , Sohani Aliyah R. , Kutok Jeffery L. , Rodig Scott J.
Published: April 2023

PDF file, 871K, S1 Chromogenic staining (DAB, brown) of paraffin-embedded DLBCL cell lines DHL4, and Toledo, untreated and BCR crosslinked, with anti-pLYN (Y396), anti-pSYK (Y323), and anti-pBTK (Y551); S2 Schematic illustration of Tissuequest analysis workflow. Individual cells are first identified by finding the nuclei (DAPI); S3 Qualitative Western blot of whole cell lysates for untreated (BCR-) and crosslinked (BCR+) cell lines; S4 S4 Chromogenic staining (DAB, brown) of two paraffin-embedded patient DLBCL specimens with anti-pLYN (Y396), anti-pSYK (Y323), and anti-pBTK (Y551); S5 (A) Schematic illustration of Tissuequest workflow extended to subcellular localization of FOXO1. In this example there are 83% of all cells that are positive for FOXO1 and 67% of the cells show cytoplasmic FOXO1 staining (67%). The ratio of these percentages is used to calculate the Fcyt score; S6 (A) Chromogenic staining (DAB, brown) of paraffin-embedded DLBCL cell lines DHL4, and Toledo, untreated and BCR crosslinked, with anti- FOXO1; S7 (A) IHC staining of paraffin-embedded DLBCL cell lines U2932, DHL6 and Toledo, untreated and crosslinked, with anti-pAKTsub (red) and DAPI (blue); S8 (A) Comparison of immunofluorescent images evaluated by an expert using a 3-tier system (0 - negative, 1 - weak positive, 2 - strong positive); S9 Comparison of FOXO1 cytoplasmic localization and BCR signaling in primary DLBCL tumors.
Supplementary Figure Legend and Table 1 from 14-3-3ζ, a Novel Androgen-Responsive Gene, Is Upregulated in Prostate Cancer and Promotes Prostate Cancer Cell Proliferation and Survival
Authors: Murata Taro , Takayama Ken-ichi , Urano Tomohiko , Fujimura Tetsuya , Ashikari Daisaku , Obinata Daisuke , Horie-Inoue Kuniko , Takahashi Satoru , Ouchi Yasuyoshi , Homma Yukio , Inoue Satoshi
Published: April 2023

PDF file, 138K, The clinical and histopathological data of the patients in the studies.
Supplementary Table 1 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 766K, Cell lines.
Supplementary Table 1 from The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Authors: deLeeuw Ronald J. , Kost Sara E. , Kakal Juzer A. , Nelson Brad H.
Published: April 2023

PDF file, 65KB, Summary of information extracted from the reviewed studies.
Supplementary Methods from LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic Signals
Authors: Flechsig Paul , Dadrich Monika , Bickelhaupt Sebastian , Jenne Jürgen , Hauser Kai , Timke Carmen , Peschke Peter , Hahn Eric W. , Gröne Hermann-Josef , Yingling Jonathan , Lahn Michael , Wirkner Ute , Huber Peter E.
Published: April 2023

PDF file, 95KB.
Supplementary Table 5 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 79KB, Antibodies used in this study.
Supplementary Figure 2 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 95K, ICs in 11 cell lines.
Supplementary Table 2 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 73KB, shGal-1 sequences.
Supplementary Figure 3 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 81KB, Gal-1 overexpression in H522.
Supplementary Figure Legend from Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Authors: Sen Malabika , Joyce Sonali , Panahandeh Mary , Li Changyou , Thomas Sufi M. , Maxwell Jessica , Wang Lin , Gooding William E. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

PDF file, 78K.
Supplementary Figure 2 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
Authors: O'Konek Jessica J. , Kato Shingo , Takao Satomi , Izhak Liat , Xia Zheng , Illarionov Petr , Besra Gurdyal S. , Terabe Masaki , Berzofsky Jay A.
Published: April 2023

PDF file, 791K, Mice were injected i.p. with 2.4 or 12 nmol of b-ManCer, or 2.4 nmol of a-GalCer or vehicle control. After 6 weeks, splenocytes were harvested and restimulated in vitro with 100 nM a-GalCer, 500 nM of b-ManCer or vehicle. IFN-g and IL-4 in culture supernatants was measured after 48 hours of stimulation. Representatives of at least 2 replicate experiments are shown. Bars represent mean�SD; *, statistically significantly different from vehicle control stimulation; #, statistically significant from corresponding stimulation in vehicle pretreated group p<0.05.
Supplementary Tables 1-2 from Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment
Authors: Yang Jilong , Ylipää Antti , Sun Yan , Zheng Hong , Chen Kexin , Nykter Matti , Trent Jonathan , Ratner Nancy , Lev Dina C. , Zhang Wei
Published: April 2023

Supplementary Tables 1-2 from Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment
Supplementary Figure 2 from Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma
Authors: Kawaguchi Atsushi , Iwadate Yasuo , Komohara Yoshihiro , Sano Masakazu , Kajiwara Koji , Yajima Naoki , Tsuchiya Naoto , Homma Jumpei , Aoki Hiroshi , Kobayashi Tsutomu , Sakai Yuko , Hondoh Hiroaki , Fujii Yukihiko , Kakuma Tatsuyuki , Yamanaka Ryuya
Published: April 2023

PDF file, 178K, Classification by cell-of-origin is associated with survival in univariate analyses.
Supplementary Table 2 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Authors: Galanis Evanthia , Anderson S. Keith , Lafky Jackie M. , Uhm Joon H. , Giannini Caterina , Kumar Shaji K. , Kimlinger Teresa K. , Northfelt Donald W. , Flynn Patrick J. , Jaeckle Kurt A. , Kaufmann Timothy J. , Buckner Jan C.
Published: April 2023

Supplementary Table 2 - PDF file 54K, SNPs Analyzed and Genotype Frequencies
Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Authors: Dosset Magalie , Godet Yann , Vauchy Charline , Beziaud Laurent , Lone Yu Chun , Sedlik Christine , Liard Christelle , Levionnois Emeline , Clerc Bertrand , Sandoval Federico , Daguindau Etienne , Wain-Hobson Simon , Tartour Eric , Langlade-Demoyen Pierre , Borg Christophe , Adotévi Olivier
Published: April 2023

PDF file - 106K
Supplementary Figure 1 from Cyclophosphamide Induces a Type I Interferon–Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
Authors: Moschella Federica , Torelli Giovanni Fernando , Valentini Mara , Urbani Francesca , Buccione Carla , Petrucci Maria Teresa , Natalino Fiammetta , Belardelli Filippo , Foà Robin , Proietti Enrico
Published: April 2023

PDF file - 237K, Schematic illustration of "lysosome" and "p53 signaling" pathways.
Supplementary Table 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 52K, An overview of the antibodies used in the present study
Supplementary Figure 6 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 135K, Analysis of hypoxia during Ang-2-VEGF-A inhibition
Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 188K, Cross-reactivity and binding affinities of A2V CrossMab and the comparator molecules bevacizumab and LC06
Supplementary Table 2 from EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions
Authors: Schussel Juliana , Zhou Xian Chong , Zhang Zhe , Pattani Kavita , Bermudez Francisco , Jean-Charles Germain , McCaffrey Thomas , Padhya Tapan , Phelan Joan , Spivakovsky Silvia , Brait Mariana , Li Ryan , Yoo Bowne Helen , Goldberg Judith D. , Rolnitzky Linda , Robbins Miriam , Kerr A. Ross , Sirois David , Califano Joseph A.
Published: April 2023

Supplementary Table 2 - PDF file 42K, Association between risk assessment and genes hypermethylation status
Supplementary Figure 1 from EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions
Authors: Schussel Juliana , Zhou Xian Chong , Zhang Zhe , Pattani Kavita , Bermudez Francisco , Jean-Charles Germain , McCaffrey Thomas , Padhya Tapan , Phelan Joan , Spivakovsky Silvia , Brait Mariana , Li Ryan , Yoo Bowne Helen , Goldberg Judith D. , Rolnitzky Linda , Robbins Miriam , Kerr A. Ross , Sirois David , Califano Joseph A.
Published: April 2023

Supplementary Figure 1 - PDF file 143K, ROC curves corresponding to the use of gene signatures, clinical exam and a combination of these. A: Risk Classification; B: EDNRB; C: DCC; D: EDNRB and DCC; E: EDNRB and Risk Classification; F: DCC and Risk Classification; G: EDNRB, DCC and Risk Classification
Supplementary Data from EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions
Authors: Schussel Juliana , Zhou Xian Chong , Zhang Zhe , Pattani Kavita , Bermudez Francisco , Jean-Charles Germain , McCaffrey Thomas , Padhya Tapan , Phelan Joan , Spivakovsky Silvia , Brait Mariana , Li Ryan , Yoo Bowne Helen , Goldberg Judith D. , Rolnitzky Linda , Robbins Miriam , Kerr A. Ross , Sirois David , Califano Joseph A.
Published: April 2023

Supplementary Data - PDF file 79K, Supplementary data revised, figure added
Supplementary Figure S4 from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
Authors: Conrad David P. , Tsang Jovian , Maclean Meaghan , Diallo Jean-Simon , Le Boeuf Fabrice , Lemay Chantal G. , Falls Theresa J. , Parato Kelley A. , Bell John C. , Atkins Harold L.
Published: April 2023

Supplementary Figure S4 - PDF file 1158K, Efficacy of EL4-based iLOV
Supplementary Figure S2 from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
Authors: Conrad David P. , Tsang Jovian , Maclean Meaghan , Diallo Jean-Simon , Le Boeuf Fabrice , Lemay Chantal G. , Falls Theresa J. , Parato Kelley A. , Bell John C. , Atkins Harold L.
Published: April 2023

Supplementary Figure S2 - PDF file 751K, Cytopathic effect induced by rhabdovirus infection
Supplementary Table 1 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer
Authors: Deng Yong-Jian , Tang Na , Liu Chao , Zhang Jiang-Yu , An Sheng-Li , Peng Yin-Li , Ma Li-Li , Li Guang-Qiu , Jiang Qiang , Hu Chun-Ting , Wang Ya-Nan , Liang Yao-Ze , Bian Xiu-Wu , Fang Wei-Gang , Ding Yan-Qing
Published: April 2023

PDF file - 83K, The 27 identified proteins with differential expression among Sph17, Sph40 and SW480 cells.
Supplementary Figure 6 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Authors: Grassilli Emanuela , Narloch Robert , Federzoni Elena , Ianzano Leonarda , Pisano Fabio , Giovannoni Roberto , Romano Gabriele , Masiero Laura , Leone Biagio Eugenio , Bonin Serena , Donada Marisa , Stanta Giorgio , Helin Kristian , Lavitrano Marialuisa
Published: April 2023

Supplementary Figure 6 - PDF file 2812K, GSK3B is activated in colon carcinoma samples
Supplementary Table 5 from Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis
Authors: Dey Parama , Rachagani Satyanarayana , Chakraborty Subhankar , Singh Pankaj K. , Zhao Xiangshan , Gurumurthy Channabasavaiah Basavaraju , Anderson Judy M. , Lele Subodh , Hollingsworth Michael A. , Band Vimla , Batra Surinder K.
Published: April 2023

XLSX file - 43K, Number of metastatic deposits for Ecd Scr and KD cell injected mice
Supplementary Table 4 from Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis
Authors: Dey Parama , Rachagani Satyanarayana , Chakraborty Subhankar , Singh Pankaj K. , Zhao Xiangshan , Gurumurthy Channabasavaiah Basavaraju , Anderson Judy M. , Lele Subodh , Hollingsworth Michael A. , Band Vimla , Batra Surinder K.
Published: April 2023

XLSX file - 11K, Expression of Ecd in metastasis from Ecd positive vs. negative pancreatic tumors
Supplementary Table 3 from Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis
Authors: Dey Parama , Rachagani Satyanarayana , Chakraborty Subhankar , Singh Pankaj K. , Zhao Xiangshan , Gurumurthy Channabasavaiah Basavaraju , Anderson Judy M. , Lele Subodh , Hollingsworth Michael A. , Band Vimla , Batra Surinder K.
Published: April 2023

XLSX file - 11K, Expression of Ecd in primary and metastatic pancreatic cancer
Supplementary Table A from Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
Authors: Komlodi-Pasztor Edina , Sackett Dan L. , Fojo Antonio Tito
Published: April 2023

PDF file - 90
Supplementary Figure 1 from Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
Authors: Zhang Yi-Xiang , van Oosterwijk Jolieke G. , Sicinska Ewa , Moss Samuel , Remillard Stephen P. , van Wezel Tom , Bühnemann Claudia , Hassan Andrew B. , Demetri George D. , Bovée Judith V.M.G. , Wagner Andrew J.
Published: April 2023

Supplementary Figure 1 - PDF file 170K, Effects of RTK inhibition in chondrosarcoma cells
Supplementary Methods, Figures 1-4, Tables 1 from A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Authors: Eigentler Thomas K. , Weide Benjamin , de Braud Filippo , Spitaleri Gianluca , Romanini Antonella , Pflugfelder Annette , González-Iglesias Reinerio , Tasciotti Annaelisa , Giovannoni Leonardo , Schwager Kathrin , Lovato Valeria , Kaspar Manuela , Trachsel Eveline , Menssen Hans D. , Neri Dario , Garbe Claus
Published: April 2023

PDF file - 667K
Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Authors: Coutinho Rita , Clear Andrew James , Owen Andrew , Wilson Andrew , Matthews Janet , Lee Abigail , Alvarez Rute , da Silva Maria Gomes , Cabeçadas José , Calaminici Maria , Gribben John G.
Published: April 2023

PDF file 54K, Supplementary Table S1 Primary antibodies and conditions of use
Supplementary Table 3 from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
Authors: Zhang Cathy C. , Pavlicek Adam , Zhang Qin , Lira Maruja E. , Painter Cory L. , Yan Zhengming , Zheng Xianxian , Lee Nathan V. , Ozeck Mark , Qiu Ming , Zong Qing , Lappin Patrick B. , Wong Anthony , Rejto Paul A. , Smeal Tod , Christensen James G.
Published: April 2023

XLS file, 129K, Description of gene expression experiments from Table 2S for analysis in R.